• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pacific Biosciences of California Inc. (Amendment)

    2/5/24 6:08:57 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PACB alert in real time by email
    SC 13G/A 1 pacbio130247sc13ga2.htm AMENDMENT NO. 2

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     ________________ 

      

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

     

    Pacific Biosciences of California, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    69404D108
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x       Rule 13d-1(b)

     

    o       Rule 13d-1(c)

     

    o       Rule 13d-1(d)

     

     

                                                                 

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 9 
     

     

    CUSIP No. 69404D108                 13G/A  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Sumitomo Mitsui Trust Holdings, Inc.  (“SMTH”)

      

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o
       

    (b) o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

    0

     

    6.

    SHARED VOTING POWER

    13,200,375

     

    7.

    SOLE DISPOSITIVE POWER

    0

     

    8.

    SHARED DISPOSITIVE POWER

    13,200,375

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    13,200,375

     

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.93%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    HC, FI

     

     Page 2 of 9 
     

      

    CUSIP No. 69404D108 13G/A  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Nikko Asset Management Co., Ltd. (“NAM”)

        

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o
       

    (b) o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

    0

     

    6.

    SHARED VOTING POWER

    13,200,375

     

    7.

    SOLE DISPOSITIVE POWER

    0

     

    8.

    SHARED DISPOSITIVE POWER

    13,200,375

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    13,200,375

     

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.93%

    12.

    TYPE OF REPORTING PERSON

     

    IA, HC, FI

     

     

     Page 3 of 9 
     

      

    Item 1(a).Name of Issuer:

     

    Pacific Biosciences of California, Inc.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    1305 O’Brien Drive Menlo Park, California 94025

     

    Item 2(a).Name of Person Filing:

     

    Sumitomo Mitsui Trust Holdings, Inc.

     

    Nikko Asset Management Co., Ltd.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    SMTH: 1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan

     

    NAM: Midtown Tower, 9-7-1 Akasaka, Minato-ku, Tokyo 107-6242, Japan

     

    Item 2(c).Citizenship:

     

    SMTH: Japan

     

    NAM: Japan

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share

     

    Item 2(e).CUSIP Number:

     

    69404D108

     

     Page 4 of 9 
     

     

    Item 3.If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    SMTH:

     

     

    (a) o  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) o  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) o  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) o  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) o  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) o  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) x  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) o  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) o  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) x  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) o  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Parent Holding Company

     

    NAM:

     

    (a) o  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) o  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) o  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) o  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) x  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) o  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) x  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) o  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) o  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) x  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) o  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

     Page 5 of 9 
     

      

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Investment Adviser, Parent Holding Company

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

     

    SMTH:    
         
      (a)   Amount beneficially owned: 13,200,375
           
      (b)   Percent of class: 4.93%
           
      (c)   Number of shares as to which such person has:
           
      (i)   Sole power to vote or to direct the vote: 0
           
      (ii)   Shared power to vote or to direct the vote: 13,200,375
           
      (iii)   Sole power to dispose or to direct the disposition of: 0
           
      (iv)  

    Shared power to dispose or to direct the disposition of: 13,200,375

           
    NAM:    
         
      (a)   Amount beneficially owned: 13,200,375
           
      (b)   Percent of class: 4.93%
           
      (c)   Number of shares as to which such person has:
           
      (i)   Sole power to vote or to direct the vote: 0
           
      (ii)   Shared power to vote or to direct the vote: 13,200,375
           
      (iii)   Sole power to dispose or to direct the disposition of: 0
           
      (iv)   Shared power to dispose or to direct the disposition of: 13,200,375

     

     Page 6 of 9 
     

     

    Item 5.Ownership of Five Percent or Less of a Class.

      

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    See Exhibit A.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 9 
     

      

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 5, 2024

     

      Sumitomo Mitsui Trust Holdings, Inc.
      (Company)
       
      /s/ Hideaki Takamiya
     

    (Signature)

     

    Hideaki Takamiya / Senior Manager of Risk
    Management Dept 

      (Name/Title)
       
      Nikko Asset Management Co.,Ltd 
      (Company)
       
      /s/ Atsushi Ohya
     

    (Signature)

     

    Atsushi Ohya / Head of Business Regulatory Compliance 

      (Name/Title)

     

     Page 8 of 9 
     

      

    Exhibit A

     

    Pursuant to the instructions in Item 7 of Schedule 13G, the securities being reported on by each of SMTH and NAM, as parent holding companies, are owned, or may be deemed to be beneficially owned, by their subsidiary Nikko Asset Management Americas, Inc., which is classified as an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

     

    Page 9 of 9

     

     

    Get the next $PACB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PACB

    DatePrice TargetRatingAnalyst
    11/11/2024Buy → Neutral
    UBS
    6/3/2024$4.00Buy
    Jefferies
    4/22/2024Overweight → Neutral
    JP Morgan
    4/18/2024$7.00 → $2.50Buy → Neutral
    Goldman
    12/14/2023$11.00Overweight
    Stephens
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    11/17/2023$13.00 → $10.00Neutral → Buy
    UBS
    More analyst ratings

    $PACB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mohr Marshall

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      6/6/25 4:10:59 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Livingston Randall S

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      6/6/25 4:10:13 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Ordonez Kathy

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      6/6/25 4:09:30 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date

      Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide NEW YORK and MENLO PARK, Calif., June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate long read sequencing platforms, to launch the largest global whole genome sequencing initiative for ALS to date. By applying PacBio's HiFi sequencing to more than 6,000 genomes from people with ALS and healthy controls, the project aims to detect structural variants, repeat expansions, and ot

      6/2/25 10:00:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio to Present at Upcoming Investor Conferences

      MENLO PARK, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 8:45 AM ET in New York, NY46th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11, 2025, at 10:40 AM ET in Miami Beach, FL Live webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com. A replay of the webcasts will be available for at least 30 days following the event. About PacBio PacBio (NASDAQ:PACB

      5/28/25 9:00:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

      MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio's HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes. Founded in 2020, Haorui Gene has quickly become a key player in blood typing genomics, deploying seven Sequel II and three R

      5/22/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Meline David W bought $176,160 worth of shares (40,000 units at $4.40) (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      3/6/24 5:36:07 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    SEC Filings

    See more
    • Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      6/6/25 4:21:08 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Pacific Biosciences of California Inc.

      SD - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      5/29/25 4:06:12 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Pacific Biosciences of California Inc.

      DEFA14A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      5/20/25 5:26:51 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pacific Biosciences downgraded by UBS

      UBS downgraded Pacific Biosciences from Buy to Neutral

      11/11/24 9:44:33 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies resumed coverage on Pacific Biosciences with a new price target

      Jefferies resumed coverage of Pacific Biosciences with a rating of Buy and set a new price target of $4.00

      6/3/24 8:16:36 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pacific Biosciences downgraded by JP Morgan

      JP Morgan downgraded Pacific Biosciences from Overweight to Neutral

      4/22/24 7:40:44 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Leadership Updates

    Live Leadership Updates

    See more
    • PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

      MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio's HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes. Founded in 2020, Haorui Gene has quickly become a key player in blood typing genomics, deploying seven Sequel II and three R

      5/22/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jim Gibson to join PacBio as Chief Financial Officer

      MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across

      3/27/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

      MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom V

      2/3/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Financials

    Live finance-specific insights

    See more
    • PacBio Announces First Quarter 2025 Financial Results

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:  Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio™ systems1228Vega™ systems28—Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspon

      5/8/25 4:15:34 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

      Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results  Preliminary Q1 2025Q1 2024Revenue$36.9 million$38.8 millionInstrument revenue$10.8 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio systems1228Vega systems28-Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9

      4/9/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results

      MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period.Instrument revenue of $15.3 million compared with $35.1 million in the prior-year period. Instrument revenue in the fourth quarter of 2024 included 23 Revio® sequencing systems and 7 Vega™ sequencing systems.Consumables revenue of $18.8 million compared with $18.9 million in the prior-year period.Service and other revenue of $5.1 million compared with $4.4 million in the prior-year period. Gross margin, opera

      2/13/25 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Pacific Biosciences of California Inc.

      SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/26/24 8:27:01 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Pacific Biosciences of California Inc.

      SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/14/24 5:52:54 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

      SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/14/24 5:48:11 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials